Groowe Groowe / Newsroom / EVAX
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

EVAX News

Evaxion A/S American Depositary Share

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

globenewswire.com
EVAX

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

globenewswire.com
EVAX

Evaxion raises $7.2 million, extending cash runway to second half of 2027

globenewswire.com
EVAX

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

globenewswire.com
EVAX

Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation

prnewswire.com
GTBP EVAX RNXT EDAP XNCR GTBP EVAX RNXT EDAP XNCR

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

globenewswire.com
EVAX

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

globenewswire.com
EVAX

Evaxion expands AI-Immunology™ platform with automated vaccine design module

globenewswire.com
EVAX

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

globenewswire.com
EVAX

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

globenewswire.com
EVAX